70 results
8-K
EX-99.1
CLSD
Clearside Biomedical Inc
12 Mar 24
Results of Operations and Financial Condition
4:16pm
Agreement under a Special Protocol Assessment (SPA) for its CoMpass Phase 3 clinical trial of belzupacap sarotalocan (bel-sar) in early-stage choroidal
424B5
CLSD
Clearside Biomedical Inc
8 Feb 24
Prospectus supplement for primary offering
4:52pm
, an assessment of our management, the general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant
8-K
EX-10.1
frq9us6gswcl03p
12 May 23
Entry into a Material Definitive Agreement
4:11pm
8-K
EX-99.3
ndxk6teq
9 Nov 22
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
8:29am
8-K
EX-99.2
nn59a
9 Nov 22
Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update
8:29am
PRE 14A
sq440
19 Apr 22
Preliminary proxy
4:36pm
8-K
EX-99.1
0zy6d
21 Dec 21
Regulation FD Disclosure
7:16am